CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
CASI Pharmaceuticals (NASDAQ:CASI), a clinical-stage biopharmaceutical company specializing in therapies for organ transplant rejection and autoimmune diseases, has announced its participation in the upcoming Cantor Global Healthcare Conference.
CEO David Cory will engage in a fireside chat on September 3, 2025, at 11:30 AM ET in New York City. The company will also conduct one-on-one investor meetings during the conference. Investors can access the live webcast through CASI's website, with a replay available for 90 days following the event.
CASI Pharmaceuticals (NASDAQ:CASI), azienda biofarmaceutica in fase clinica specializzata in terapie per il rigetto d'organo e le malattie autoimmuni, ha comunicato la sua partecipazione al prossimo Cantor Global Healthcare Conference.
Il CEO David Cory parteciper脿 a una fireside chat il 3 settembre 2025 alle 11:30 ET a New York City. La societ脿 terr脿 inoltre incontri individuali con investitori durante la conferenza. Gli investitori potranno seguire la diretta streaming dal sito di CASI; la replica sar脿 disponibile per 90 giorni dopo l'evento.
CASI Pharmaceuticals (NASDAQ:CASI), una compa帽铆a biofarmac茅utica en fase cl铆nica especializada en terapias para el rechazo de 贸rganos y enfermedades autoinmunes, ha anunciado su participaci贸n en la pr贸xima Cantor Global Healthcare Conference.
El CEO David Cory participar谩 en una fireside chat el 3 de septiembre de 2025 a las 11:30 AM ET en la ciudad de Nueva York. La compa帽铆a tambi茅n mantendr谩 reuniones uno a uno con inversores durante la conferencia. Los inversores podr谩n acceder a la transmisi贸n en vivo a trav茅s del sitio web de CASI; la repetici贸n estar谩 disponible durante 90 d铆as tras el evento.
CASI Pharmaceuticals (NASDAQ:CASI)電� 鞛リ赴 鞚挫嫕 瓯半秬 氚橃潙 氚� 鞛愱皜氅挫棴 歆堩櫂 旃橂鞝滌棎 韸鬼檾霅� 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎届偓搿�, 雼り皜鞓る姅 Cantor Global Healthcare Conference鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
CEO David Cory電� 2025雲� 9鞗� 3鞚� 霃欕秬 鞁滉皠(ET) 旮办 鞓れ爠 11鞁� 30攵�鞐� 雺挫殨鞐愳劀 鞐措Μ電� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳劃頃╇媹雼�. 須岇偓電� 旎嵓霟办姢 旮瓣皠 霃欖晥 韴瀽鞛愳檧鞚� 1:1 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� CASI 鞗轨偓鞚错姼毳� 韱淀暣 霛检澊敫� 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 頄夓偓電� 膦呺 頉� 90鞚缄皠 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
CASI Pharmaceuticals (NASDAQ:CASI), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les traitements du rejet d'organe et des maladies auto-immunes, a annonc茅 sa participation 脿 la prochaine Cantor Global Healthcare Conference.
Le PDG David Cory participera 脿 une 芦 fireside chat 禄 le 3 septembre 2025 脿 11h30 (heure ET) 脿 New York. La soci茅t茅 tiendra 茅galement des r茅unions individuelles avec des investisseurs pendant la conf茅rence. Les investisseurs pourront acc茅der au webdiffusion en direct via le site de CASI ; un replay sera disponible pendant 90 jours apr猫s l'茅v茅nement.
CASI Pharmaceuticals (NASDAQ:CASI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien gegen Organabsto脽ung und Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Cantor Global Healthcare Conference angek眉ndigt.
CEO David Cory wird am 3. September 2025 um 11:30 Uhr ET in New York City an einem Fireside Chat teilnehmen. Das Unternehmen wird au脽erdem Einzelgespr盲che mit Investoren w盲hrend der Konferenz f眉hren. Investoren k枚nnen das Live-Webcast 眉ber die CASI-Website verfolgen; eine Aufzeichnung steht 90 Tage nach der Veranstaltung zur Verf眉gung.
- None.
- None.
SAN FRANCISCO, CA / / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM ET in New York City. CASI will also host one-on-one meetings with investors at the conference.
A live webcast of the fireside chat will be available on the CASI Pharmaceuticals website at under the "Investors" tab. A replay of the webcast will be available for 90 days after the live event.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) and plans to initiate the study in third quarter of 2025.
More information on CASI is available at .
COMPANY CONTACT:
Ingrid Choong, PhD
650-619-6115
[email protected]
SOURCE: CASI Pharmaceuticals
View the original on ACCESS Newswire
FAQ
When is CASI Pharmaceuticals (CASI) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access CASI Pharmaceuticals' presentation at the Cantor Conference?
What type of meetings will CASI Pharmaceuticals host at the Cantor Healthcare Conference?
What is CASI Pharmaceuticals' main business focus?
